S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
common shares · Exchange Nasdaq · Selling stockholders only · Use of proceeds Common shares offered by existing Registered Shareholders in a direct listing, with no issuer proceeds indicated
2026-11-19 · 0001493152-26-053312
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
First tracked pre-IPO filing for this issuer.
common shares · Exchange Nasdaq · Ticker BIRCH · Flags foreign_private_issuer, self_underwritten
2026-10-09 · 0001493152-26-046585
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Common Shares · Exchange Nasdaq
BirchBioMed Inc. is a pre-revenue clinical-stage biopharmaceutical company with a limited operating history and escalating losses. The company focuses on developing product candidates across its NHP/Cosmetics and Pharmaceutical Rx platforms, with FS2 topical cream approved in Canada as an NHP but no products currently on the market. Key challenges include securing FDA approval in the U.S., reliance on partnerships for commercialization, and significant financial and operational risks. The company anticipates continued losses and requires additional capital to advance clinical programs and achieve profitability.
2026-08-12 · 0001493152-26-037435
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
The current DRS/A updates BirchBioMed's financial disclosure to include unaudited results for the three months ended March 31, 2026, along with year ended December 31, 2025 and comparative periods. The company remains pre-revenue and clinical stage, with cash of $3,186,510 at March 31, 2026, accumulated losses of $25,154,480, and an expectation that additional capital will be needed to fund operations. Recent financing was primarily through convertible promissory notes and warrant exercises, and $9.08 million of convertible notes were converted into 3,308,737 common shares at $3.00 per share on February 15, 2026. Operating expense discussion emphasizes public-company readiness and direct-listing-related costs, while R&D spending is now more concentrated in the idiopathic pulmonary fibrosis program, with lower burn and type 1 diabetes activity relative to prior periods.
2026-07-01 · 0001493152-26-031579
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
2026-05-01 · 0001493152-26-020930
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
BirchBioMed's DRS/A updates its draft financial and liquidity disclosure for a pre-revenue, clinical-stage biopharmaceutical company after changing its fiscal year-end to December 31. The current draft completes FY2025 results, including R&D expense of $219,035, G&A of $3,240,033, net loss of $4,553,942, and operating cash use of $2,201,764. It also adds Q4 2025 results, cash of $3,431,079, an 18-month stated runway, and details on a 2025 convertible note offering of 41 notes totaling $4,870,661 with 8% interest and 2028 maturities.
2026-04-02 · 0001493152-26-014961
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
BirchBioMed Inc. is a pre-revenue clinical-stage biopharmaceutical company focused on developing therapies for conditions like scars, idiopathic pulmonary fibrosis, and type 1 diabetes. The company recently changed its fiscal year end from September 30 to December 31, beginning in 2025, leading to limited comparability between fiscal periods. Financially, the company reported a net loss of $3.36 million for the year ended December 31, 2025, with operating expenses driven by research and development and general administrative costs. Liquidity concerns persist, as the company relies on external financing and faces uncertainty about its ability to continue as a going concern.
2026-02-13 · 0001493152-26-006792
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
BirchBioMed Inc. outlines significant risks associated with its product development and regulatory approval processes. The company highlights challenges in obtaining and maintaining regulatory approvals, including potential delays due to disagreements with clinical trial designs, failure to demonstrate efficacy, and manufacturing issues. It also emphasizes the impact of U.S. government policy changes, such as reduced funding for agencies like the FDA, which could hinder its operations. The filing underscores dependencies on third-party contractors, patient enrollment difficulties, and the uncertainty of orphan drug exclusivity. Key risks include clinical trial failures, regulatory non-compliance, and reliance on key personnel.
2025-12-23 · 0001493152-25-028873